These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29342922)

  • 1. Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
    Wyganowska-Świątkowska M; Matthews-Kozanecka M; Matthews-Brzozowska T; Skrzypczak-Jankun E; Jankun J
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
    Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
    Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition by Epigallocatechin Gallate of IL-1-Induced Urokinase-Type Plasminogen Activator Expression and Collagen Degradation by Corneal Fibroblasts.
    Sugioka K; Yoshida K; Murakami J; Itahashi M; Mishima H; Nishida T; Kusaka S
    Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):2895-2903. PubMed ID: 31266061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
    Farabegoli F; Papi A; Orlandi M
    Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis.
    Yamakawa S; Asai T; Uchida T; Matsukawa M; Akizawa T; Oku N
    Cancer Lett; 2004 Jul; 210(1):47-55. PubMed ID: 15172120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells.
    Kim MH; Jung MA; Hwang YS; Jeong M; Kim SM; Ahn SJ; Shin BA; Ahn BW; Jung YD
    Eur J Pharmacol; 2004 Mar; 487(1-3):1-6. PubMed ID: 15033370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
    Ho YC; Yang SF; Peng CY; Chou MY; Chang YC
    J Oral Pathol Med; 2007 Nov; 36(10):588-93. PubMed ID: 17944751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
    Starbuck JM; Llambrich S; Gonzàlez R; Albaigès J; Sarlé A; Wouters J; González A; Sevillano X; Sharpe J; De La Torre R; Dierssen M; Vande Velde G; Martínez-Abadías N
    Sci Rep; 2021 Feb; 11(1):4715. PubMed ID: 33633179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells.
    Maeda-Yamamoto M; Suzuki N; Sawai Y; Miyase T; Sano M; Hashimoto-Ohta A; Isemura M
    J Agric Food Chem; 2003 Mar; 51(7):1858-63. PubMed ID: 12643642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
    Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
    PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia.
    Park JW; Hong JS; Lee KS; Kim HY; Lee JJ; Lee SR
    J Nutr Biochem; 2010 Nov; 21(11):1038-44. PubMed ID: 19962294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
    Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
    Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes.
    Ahmed S; Wang N; Lalonde M; Goldberg VM; Haqqi TM
    J Pharmacol Exp Ther; 2004 Feb; 308(2):767-73. PubMed ID: 14600251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.
    Farabegoli F; Govoni M; Spisni E; Papi A
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
    Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
    Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.